NASDAQ:CRBP Corbus Pharmaceuticals Q3 2026 Earnings Results & Report $3.84 +0.32 (+8.95%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Corbus Pharmaceuticals missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$1.81 versus the -$1.27 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call8:00 AM ET Corbus Pharmaceuticals EPS ResultsActual EPS-$1.81Consensus EPS -$1.27Beat/MissMissed by -$0.54One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCorbus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.67 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Corbus Pharmaceuticals Q3 2026 Earnings FAQ Did Corbus Pharmaceuticals beat earnings estimates for Q3 2026? Corbus Pharmaceuticals (NASDAQ:CRBP) reported earnings of -$1.81 per share for Q3 2026, missing the consensus estimate of -$1.27. The report was announced on Tuesday, November 10, 2026. Corbus Pharmaceuticals Earnings HeadlinesCorbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update8 minutes ago | finance.yahoo.comCorbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update8 minutes ago | finance.yahoo.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Corbus Pharmaceuticals: Q3 earnings snapshot8 minutes ago | msn.comCorbus Pharmaceuticals (CRBP) Set to Release Quarterly Earnings on WednesdayNovember 10 at 1:57 AM | americanbankingnews.comCorbus Pharmaceuticals to Participate in Upcoming Investor Conferences in NovemberNovember 5, 2026 | markets.businessinsider.comSee More Corbus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corbus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corbus Pharmaceuticals and other key companies, straight to your email. Email Address About Corbus PharmaceuticalsCorbus Pharmaceuticals (NASDAQ:CRBP) is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease. Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers. The company has also pursued antibody-drug conjugate programs, including CRB-701, which is designed to target Nectin-4, a protein expressed by various solid tumors. Founded in 2009 and based in Norwood, Massachusetts, Corbus previously developed lenabasum, an investigational cannabinoid receptor type 2 agonist for inflammatory and fibrotic diseases. The company later shifted its primary strategic focus toward oncology. Corbus is led by Chief Executive Officer Yuval Cohen, Ph.D., who has been associated with the company since its early development.View Corbus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
